Estrogen modulates serotonin effects on vasoconstriction through Src inhibition

被引:12
作者
Kim, Jae Gon [1 ]
Leem, Young-Eun [2 ,3 ]
Kwon, Ilmin [4 ]
Kang, Jong-Sun [2 ,3 ]
Bae, Young Min [1 ]
Cho, Hana [3 ,5 ]
机构
[1] Konkuk Univ, Res Inst Med Sci, Dept Physiol, KU Open Innovat Ctr,Sch Med, Chungju, South Korea
[2] Sungkyunkwan Univ, Dept Mol Cell Biol, Sch Med, Suwon, South Korea
[3] Sungkyunkwan Univ, Single Cell Network Res Ctr, Sch Med, Suwon, South Korea
[4] Sungkyunkwan Univ, Dept Anat & Cell Biol, Sch Med, Suwon, South Korea
[5] Sungkyunkwan Univ, Dept Physiol, Sch Med, Suwon, South Korea
基金
新加坡国家研究基金会;
关键词
NITRIC-OXIDE SYNTHASE; SMOOTH-MUSCLE-CELLS; VASCULAR INJURY RESPONSE; RAT MESENTERIC-ARTERY; RECEPTOR-BETA; 5-HT2A RECEPTOR; CARDIOVASCULAR RISK; HORMONE-THERAPY; CORONARY-ARTERY; PLUS PROGESTIN;
D O I
10.1038/s12276-018-0193-z
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Estrogen has diverse effects on cardiovascular function, including regulation of the contractile response to vasoactive substances such as serotonin. The serotonin system recently emerged as an important player in the regulation of vascular tone in humans. However, hyperreactivity to serotonin appears to be a critical factor for the pathophysiology of hypertension. In this study, we examined the modulatory mechanisms of estrogen in serotonin-induced vasoconstriction by using a combinatory approach of isometric tension measurements, molecular biology, and patch-clamp techniques. 17 beta-Estradiol (E2) elicited a significant and concentration-dependent relaxation of serotonin-induced contraction in deendothelialized aortic strips isolated from male rats. E2 triggered a relaxation of serotonin-induced contraction even in the presence of tamoxifen, an estrogen receptor antagonist, suggesting that E2-induced changes are not mediated by estrogen receptor. Patch-clamp studies in rat arterial myocytes showed that E2 prevented Kv channel inhibition induced by serotonin. Serotonin increased Src activation in arterial smooth muscle required for contraction, which was significantly inhibited by E2. The estrogen receptor-independent inhibition of Src by E2 was confirmed in HEK293T cells that do not express estrogen receptor. Taken together, these results suggest that estrogen exerts vasodilatory effects on serotonin-precontracted arteries via Src, implying a critical role for estrogen in the prevention of vascular hyperreactivity to serotonin.
引用
收藏
页码:1 / 9
页数:9
相关论文
共 51 条
  • [11] A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease
    Grodstein, F
    Manson, JE
    Colditz, GA
    Willett, WC
    Speizer, FE
    Stampfer, MJ
    [J]. ANNALS OF INTERNAL MEDICINE, 2000, 133 (12) : 933 - 941
  • [12] Estrogen receptor β -: a new dimension in estrogen mechanism of action
    Gustafsson, JÅ
    [J]. JOURNAL OF ENDOCRINOLOGY, 1999, 163 (03) : 379 - 383
  • [13] Estrogen receptor beta - Getting in on the action?
    Gustafsson, JA
    [J]. NATURE MEDICINE, 1997, 3 (05) : 493 - 494
  • [14] Menopause management: a cardiovascular risk-based approach
    Haines, C. J.
    Farrell, E.
    [J]. CLIMACTERIC, 2010, 13 (04) : 328 - 339
  • [15] Serotonin dilemma in postmenopausal women: Is it low or high?
    Haliloglu, Berna
    Aksungar, Fehime Berth
    Ilter, Erdin
    Akin, Figen Temelli
    Mutlu, Nilgun
    Peker, Hakan
    Ozden, Selcuk
    [J]. MATURITAS, 2008, 60 (02) : 148 - 152
  • [16] Harman S Mitchell, 2006, Gend Med, V3, P254, DOI 10.1016/S1550-8579(06)80214-7
  • [17] Membrane estrogen receptor engagement activates endothelial nitric oxide synthase via the PI3-kinase-Akt pathway in human endothelial cells
    Haynes, MP
    Sinha, D
    Russell, KS
    Collinge, M
    Fulton, D
    Morales-Ruiz, M
    Sessa, WC
    Bender, JR
    [J]. CIRCULATION RESEARCH, 2000, 87 (08) : 677 - 682
  • [18] Hodis Howard N, 2008, Cleve Clin J Med, V75 Suppl 4, pS3
  • [19] Identification and Characterization of New Mechanisms in Vascular Oestrogen Signalling
    Holm, Anders
    Nilsson, Bengt-Olof
    [J]. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2013, 113 (05) : 287 - 293
  • [20] Noncardiovascular disease outcomes during 6.8 years of hormone therapy - Heart and Estrogen/progestin Replacement Study follow-up (HERS II)
    Hulley, S
    Furberg, C
    Barrett-Connor, E
    Cauley, J
    Grady, D
    Haskell, W
    Knopp, R
    Lowery, M
    Satterfield, S
    Schrott, H
    Vittinghoff, E
    Hunninghake, D
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (01): : 58 - 66